Over
Nieuwscentrum

Zoektermen

Philips maakt cijfers tweede kwartaal bekend

 

Philips behaalt in het tweede kwartaal een vergelijkbare omzetgroei van 3% naar EUR 5,9 miljard, een verbetering van de gecorrigeerde EBITA van 9% naar EUR 544 miljoen en een nettoresultaat van EUR 431 miljoen

25 juli 2016

Kerncijfers tweede kwartaal
 

  • De vergelijkbare omzet van het HealthTech-portfolio bleef groeien met 5%
  • De gecorrigeerde EBITA bedroeg EUR 544 miljoen, ofwel 9,3% van de omzet, vergeleken met 8,4% van de omzet in het tweede kwartaal van 2015
  • De EBITA kwam uit op EUR 464 miljoen, ofwel 7,9% van de omzet, tegenover 7,5% van de omzet in het tweede kwartaal van 2015
  • Het bedrijfsresultaat (EBIT) bedroeg EUR 376 miljoen, vergeleken met EUR 349 miljoen in het tweede kwartaal van 2015
  • Het nettoresultaat bedroeg EUR 431 miljoen, inclusief een vergoeding van EUR 144 miljoen als gevolg van de arbitragezaak tegen Funai, tegenover EUR 274 miljoen in het tweede kwartaal van 2015
  • De operationele kasstroom was EUR 318 miljoen, vergeleken met EUR 186 miljoen in het tweede kwartaal van 2015, met een vrije kasinstroom van EUR 127 miljoen, tegenover een vrije uitgaande kasstroom van EUR 30 miljoen in het tweede kwartaal van 2015.


Frans van Houten, CEO:


“Philips heeft in het tweede kwartaal van 2016 solide resultaten geboekt. De vergelijkbare omzet is met 3% gegroeid en onze HealthTech-activiteiten hebben een sterke groei van 5% gerealiseerd. Dankzij ons transformatieprogramma Accelerate! zijn de operationele resultaten van de meeste onderdelen verder verbeterd, terwijl we blijven investeren in kwaliteit en innovatie.

Ik ben verheugd over de succesvolle notering van Philips Lighting aan de Euronext in Amsterdam per eind mei. Met deze gedenkwaardige stap kan Philips zich nu volledig richten op de geweldige kansen op het gebied van gezondheidstechnologie, terwijl voor Philips Lighting hetzelfde geldt in de groeiende markt voor energiezuinige verlichting. Philips heeft momenteel een meerderheidsbelang in Philips Lighting, maar streeft ernaar dit in de komende jaren volledig te verkopen.

Onze vooruitzichten voor 2016 blijven ongewijzigd, waarbij we verwachten dat de resultaten in de tweede helft van het jaar verder verbeteren. We zijn echter bezorgd over de toegenomen risico's door volatiliteit in een aantal markten.”

 

HealthTech


“Our HealthTech portfolio grew 5%, driven by businesses in Personal Health and Connected Care & Health Informatics. We were ableto drive further operational improvements while keeping up our significant investments in quality and innovation, including in healthinformatics, wearable patient monitoring solutions and digital pathology.


Equipment-order intake remained uneven and fell by 1% on a currency-comparable basis in the quarter. However, we expect good order intake growth in the second half of the year.”


The Personal Health businesses grew by 9% on a comparable basis, with the Adjusted EBITA margin improving by 170 basis points.The Diagnosis & Treatment businesses posted comparable sales growth of 1%, and the Adjusted EBITA margin improved by 20 basispoints. In the Connected Care & Health Informatics businesses, comparable sales grew by 6%, while the Adjusted EBITA margin improved by 110 basis points.

 

  • In line with Philips’ strategy of building multi-year, strategic partnerships, the company signed a USD 36 million agreement with the Medical University of South Carolina Health focused on integrated patient monitoring solutions. In Europe, Philips signed a EUR 19 million agreement with Heart Hospital in Tampere, Finland, to jointly innovate in cardiac care.
  • Strengthening its Digital Pathology business, Philips acquired PathXL, an innovator in digital pathology image analysis, workflow software and educational tools. Philips also signed a licensing agreement with Visiopharm to offer their breast cancer panel software algorithms with Philips’ IntelliSite digital pathology solution to support pathologists in providing an objective diagnosis of breast cancer.
  • Building on Philips’ expertise in sleep and respiratory care, the company launched the cloud-based Patient Adherence Management Service, which supports new patients’ transition to sleep therapy.
  • The Personal Care business successfully launched the OneBlade hybrid styler that trims, shaves and styles in France, the UK, Germany and North America. The Oral Healthcare business introduced the Philips Sonicare FlexCare Platinum Connected toothbrush, its latest innovation that uses Smart Sensor technology to help consumers optimize their brushing routine.
  • Within the Image-Guided Therapy business, Philips Volcano delivered another strong performance with double-digit comparable sales growth and continued operational improvements. This was driven by growth across the smart catheter product portfolio, synergies with the Image-Guided Therapy Systems business and expansion into new geographies.
  • Building on its commitment to sustainability, Philips launched its new 5-year ‘Healthy people, sustainable planet’ program to improve the lives of 2.5 billion people per year, increase its green revenues to 70% of sales, generate 15% of its sales from circular revenues and become carbon-neutral in its operations by 2020.


Lighting


On May 27, 2016, Philips Lighting was listed and started trading on Euronext in Amsterdam under the symbol ‘LIGHT’. Following the listing of Philips Lighting, Philips retains a 71.225% stake and continues to consolidate Philips Lighting.


In the second quarter, comparable sales in Philips Lighting declined by 1%, while Adjusted EBITA improved by 180 basis points to 9.3% of sales. Full details about the financial performance of Philips Lighting in the second quarter were published on July 22, 2016. The related report can be accessed here.


Separation costs

Costs related to the separation of Philips Lighting amounted to EUR 45 million in the second quarter of 2016. For the second half of 2016, Philips expects separation costs to be in the range of EUR 65–85 million. Another EUR 38 million of costs related to the listing of Philips Lighting were booked through equity in the second quarter of 2016.


Cost savings

Overhead cost savings amounted to EUR 19 million in the second quarter. The Design for Excellence (DfX) program generated EUR 86 million of incremental procurement savings in the quarter. The End2End improvement program achieved EUR 45 million in productivity gains.


Miscellaneous

As of June 30, 2016, Philips had completed 91% of the 3-year EUR 1.5 billion share buy-back program.

 

Quarterly Report

Second quarter results 2016 - Quarterly Report


Presentation

Second quarter results 2016 - Quarterly Results Presentation

 

Conference call and audio webcast

A conference call with Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, to discuss the results will start at 10:00 am CET, July 25, 2016. A live audio webcast of the conference call will be available through the link below.
Q2 2016 - Second quarter 2016 results conference call audio webcast

 

More information about Frans van Houten and Abhijit Bhattacharya

Click here for Mr. van Houten's CV and images

Click here for Mr. Bhattacharya's CV and images

Download
Strategic partnership with the Medical University of South Carolina Health
Download high-res
Download
Philips expands digital pathology solutions with acquisition of PathXL
Download high-res
Download
Introduction of Philips Sonicare FlexCare Platinum Connected
Download high-res

For further information, please contact:

Joost Akkermans

Philips Group Communications

Tel.: +31 6 3175 8996

E-mail: joost.akkermans@philips.com

 

Ben Zwirs

Philips Group Communications

Tel.: +31 6 15213446

E-mail: ben.zwirs@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company, headquartered in the Netherlands, is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other important information

 

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.


These factors include but are not limited to domestic and global economic and business conditions, developments within the euro zone, the successful implementation of Philips’ strategy and the ability to realize the benefits of this strategy, the ability to develop and market new products, changes in legislation, legal claims, changes in exchange and interest rates, changes in tax rates, pension costs and actuarial assumptions, raw materials and employee costs, the ability to identify and complete successful acquisitions, and to integrate those acquisitions into the business, the ability to successfully exit certain businesses or restructure the operations, the rate of technological changes, political, economic and other developments in countries where Philips operates, industry consolidation and competition and the state of international capital markets as they may affect the timing and nature of the dispositions by Philips of its interests in the Lighting business and the combined Lumileds and Automotive businesses. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see the Risk management chapter included in the Annual Report 2015.


Third-party market share data

Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.


Use of non-GAAP information

In presenting and discussing the Philips Group financial position, operating results and cash flows, management uses certain non-GAAP financial measures. These non-GAAP financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used in conjunction with the most directly comparable IFRS measures. Non-GAAP financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-GAAP measures to the most directly comparable IFRS measures is contained in this document. Further information on non-GAAP measures can be found in the Annual Report 2015.


Use of fair-value measurements

In presenting the Philips Group financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2015. Independent valuations may have been obtained to support management’s determination of fair values.

 

Presentation

All amounts are in millions of euros unless otherwise stated. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2015, unless otherwise stated.


Prior-period financial statements have been restated to reflect a reclassification of net defined-benefit post-employment plan obligations to Long-term provisions. For more details see note 1, Significant accounting policies.


Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.